TherapeuticsMD (NASDAQ:TXMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Wednesday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TherapeuticsMD stock opened at $1.58 on Wednesday. The business has a 50 day moving average of $1.70 and a 200 day moving average of $1.85. TherapeuticsMD has a 52 week low of $1.43 and a 52 week high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The company had revenue of $0.23 million during the quarter.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC acquired a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.